Junfeng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junfeng Zhao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Junling Jiang
Department of Urology , Henan Provincial Hospital of Traditional Chinese Medicine , Zhengzhou , Henan 450002 , China
3 shared publicationsLei Zhou
Department of Urology , Henan Provincial Hospital of Traditional Chinese Medicine , Zhengzhou , Henan 450002 , China
3 shared publicationsLunwei Tai
The Second Clinical Medical College of Henan University of Traditional Chinese Medicine , Zhengzhou , Henan, 450002 , China
3 shared publicationsShengyou Song
The Second Clinical Medical College of Henan University of Traditional Chinese Medicine , Zhengzhou , Henan, 450002 , China
3 shared publicationsYuqi Xu
Department of Urology, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China
2 shared publicationsHaixiang Feng
The Second Clinical Medical College of Henan University of Chinese Medicine, Henan
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1975498
Renal cell carcinoma organoids: establishment, applications, and clinical translation—current evidence, technical challenges, and future directions
Renal cell carcinoma (RCC) is characterized by marked histological, molecular, and spatial heterogeneity, which contributes to substantial interpatient variability in responses to targeted therapies, immune checkpoint inhibitors, and combination regimens. Conventional two-dimensional cultures and animal models are limited in their ability to simultaneously recapitulate patient-specific tumor features, maintain biological fidelity, and support experimental throughput. Tumor organoids can be expanded in three-dimensional culture while retaining, to varying degrees, the histological and molecular characteristics of their tumors of origin, thereby providing a complementary platform for RCC disease modeling, investigation of drug resistance mechanisms, and functional drug testing. This review is structured according to the source of evidence and the maturity of clinical translation. We summarize the establishment, culture, and quality assessment of RCC patient-derived organoids, three-dimensional tumor spheroids, stem cell-derived kidney organoids, air–liquid interface cultures, and organ-on-chip models, with particular emphasis on distinguishing direct evidence from RCC organoid studies, mechanistic evidence from non-organoid RCC models, and methodological evidence derived from other cancer types. Current evidence supports the use of RCC organoids for preserving tumor phenotypes, investigating tumor heterogeneity, evaluating responses to targeted therapies, and validating mechanisms of drug resistance. However, clinical translation remains limited by variable model-establishment efficiency and stability, incomplete recapitulation of the tumor microenvironment, and insufficient validation against patient outcomes. Future research should improve model representativeness through multiregional and longitudinal sampling, chemically defined matrices, multicellular co-culture systems, vascularized and microfluidic platforms, automated high-content screening, and single-cell and spatial multi-omics approaches. Analytical validity, clinical validity, and clinical utility should be evaluated as distinct but complementary dimensions of translational performance. At present, RCC organoids are best positioned as tools for mechanistic investigation and adjunctive prioritization of therapeutic options rather than as standalone platforms for treatment decision-making independent of pathological classification, molecular testing, and established clinical guidelines.
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1975498
Open AccessRenal cell carcinoma organoids: establishment, applications, and clinical translation—current evidence, technical challenges, and future directions
Renal cell carcinoma (RCC) is characterized by marked histological, molecular, and spatial heterogeneity, which contributes to substantial interpatient variability in responses to targeted therapies, immune checkpoint inhibitors, and combination regimens. Conventional two-dimensional cultures and animal models are limited in their ability to simultaneously recapitulate patient-specific tumor features, maintain biological fidelity, and support experimental throughput. Tumor organoids can be expanded in three-dimensional culture while retaining, to varying degrees, the histological and molecular characteristics of their tumors of origin, thereby providing a complementary platform for RCC disease modeling, investigation of drug resistance mechanisms, and functional drug testing. This review is structured according to the source of evidence and the maturity of clinical translation. We summarize the establishment, culture, and quality assessment of RCC patient-derived organoids, three-dimensional tumor spheroids, stem cell-derived kidney organoids, air–liquid interface cultures, and organ-on-chip models, with particular emphasis on distinguishing direct evidence from RCC organoid studies, mechanistic evidence from non-organoid RCC models, and methodological evidence derived from other cancer types. Current evidence supports the use of RCC organoids for preserving tumor phenotypes, investigating tumor heterogeneity, evaluating responses to targeted therapies, and validating mechanisms of drug resistance. However, clinical translation remains limited by variable model-establishment efficiency and stability, incomplete recapitulation of the tumor microenvironment, and insufficient validation against patient outcomes. Future research should improve model representativeness through multiregional and longitudinal sampling, chemically defined matrices, multicellular co-culture systems, vascularized and microfluidic platforms, automated high-content screening, and single-cell and spatial multi-omics approaches. Analytical validity, clinical validity, and clinical utility should be evaluated as distinct but complementary dimensions of translational performance. At present, RCC organoids are best positioned as tools for mechanistic investigation and adjunctive prioritization of therapeutic options rather than as standalone platforms for treatment decision-making independent of pathological classification, molecular testing, and established clinical guidelines.
- Open Access
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 20 (1)
Lathyrol affects the expression of AR and PSA and inhibits the malignant behavior of RCC cells
Objective: To investigate how lathyrol affects aggressive behaviors and related proteins of the androgen receptor (AR) 786-O cells. Methods: 786-O cells were cultured in vitro and divided into these groups at random: the dimethylsulfoxide (DMSO) control group (A group), negative control group (B group), and experimental group (C group). Cells in A group were grown in DMSO working medium (contained RPMI 1640 medium and 1% DMSO), B group cells were cultured in nilutamide working medium (contained DMSO working medium and 325 μg/mL nilutamide), while those in C group were cultured in lathyrol working medium (contained DMSO working medium and 300 μg/mL lathyrol). Cell proliferation was measured via CCK-8 assays, and cell apoptosis was examined through terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining. Scratch tests and Transwell invasion tests were used to evaluate cell movement and penetration. The expression information about p-AR, AR, p-Akt, ki67, caspase3, cleaved-caspase3, Bcl-2, Bax, caspase9, cleaved-caspase9, and GAPDH proteins was investigated through western blotting. Immunocytochemistry was used to identify the 786-O cells’ secretion level of matrix metalloproteinase 2 (MMP2), MMP9, and prostate-specific antigen (PSA) proteins. Results: The negative control and experimental groups’ cells exhibited reduced proliferation, migration, and invasion and increased apoptosis after 24 h treatment. Furthermore, these two group cells exhibited a notable reduction in the status of Ki67, Bcl-2, MMP2, MMP9, and p-Akt ( P < 0.05) and significantly increased the expressions of AR, p-AR, Bax, cleaved-caspase3, and cleaved-caspase9 ( P < 0.05). There was no statistical distance in PSA, caspase3, and caspase9 expressions among the three groups ( P > 0.05). Conclusion: In vitro, lathyrol and nilutamide exert notable anticancer effects by effectively suppressing the proliferation, migration, and invasion of 786-O cells while also inducing apoptosis.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 20 (1)
Open AccessLathyrol affects the expression of AR and PSA and inhibits the malignant behavior of RCC cells
Objective: To investigate how lathyrol affects aggressive behaviors and related proteins of the androgen receptor (AR) 786-O cells. Methods: 786-O cells were cultured in vitro and divided into these groups at random: the dimethylsulfoxide (DMSO) control group (A group), negative control group (B group), and experimental group (C group). Cells in A group were grown in DMSO working medium (contained RPMI 1640 medium and 1% DMSO), B group cells were cultured in nilutamide working medium (contained DMSO working medium and 325 μg/mL nilutamide), while those in C group were cultured in lathyrol working medium (contained DMSO working medium and 300 μg/mL lathyrol). Cell proliferation was measured via CCK-8 assays, and cell apoptosis was examined through terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining. Scratch tests and Transwell invasion tests were used to evaluate cell movement and penetration. The expression information about p-AR, AR, p-Akt, ki67, caspase3, cleaved-caspase3, Bcl-2, Bax, caspase9, cleaved-caspase9, and GAPDH proteins was investigated through western blotting. Immunocytochemistry was used to identify the 786-O cells’ secretion level of matrix metalloproteinase 2 (MMP2), MMP9, and prostate-specific antigen (PSA) proteins. Results: The negative control and experimental groups’ cells exhibited reduced proliferation, migration, and invasion and increased apoptosis after 24 h treatment. Furthermore, these two group cells exhibited a notable reduction in the status of Ki67, Bcl-2, MMP2, MMP9, and p-Akt ( P < 0.05) and significantly increased the expressions of AR, p-AR, Bax, cleaved-caspase3, and cleaved-caspase9 ( P < 0.05). There was no statistical distance in PSA, caspase3, and caspase9 expressions among the three groups ( P > 0.05). Conclusion: In vitro, lathyrol and nilutamide exert notable anticancer effects by effectively suppressing the proliferation, migration, and invasion of 786-O cells while also inducing apoptosis.
- Open Access
- 4 July 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-17
Lathyrol reduces the RCC invasion and incidence of EMT via affecting the expression of AR and SPHK2 in RCC mice
Objective: To investigate the effects of Lathyrol on the expression of androgen receptor (AR) and sphingosine kinase 2 (SPHK2) in renal cell carcinoma (RCC) mice and to further explore the mechanism by which Lathyrol inhibits the invasion and incidence of epithelial-mesenchymal transition (EMT). Methods: An RCC xenograft mouse model was constructed, and the mice were randomly divided into a model group, an experiment group and a negative control group. The experiment group was intragastrically gavaged with Lathyrol solution (20 mg/kg), the model group was intragastrically gavaged with 0.9% NaCl (same volume as that used in the experiment group), and the negative control group was injected intraperitoneally with 2 mg/kg cisplatin aqueous solution. Changes in the body weight and tumor volume of the mice were recorded. Western blot (WB) was used to assess the protein expression levels of AR, p-AR, CYP17A1, PARP1, E-cadherin, N-cadherin, vimentin, α-SMA, β-catenin, and ZO-1. Protein expression levels of SPHK2, metal matrix protease 2 (MMP2), MMP9 and urokinase-type plasminogen activator (uPA) in tumor tissues were assessed by immunohistochemistry (IHC). AR expression in tumor tissues was assessed after immunofluorescence (IF) staining. Results: After 14 days of drug administration, compared with that in the model group, the tumor volumes in the negative control and experiment groups were lower; the difference in tumor volume among the model, control and experiment groups was statistically significant (P < 0.05). The differences in body weight among the three groups were not statistically significant (P > 0.05). In the model group, the protein expression levels of AR, p-AR, CYP17A1, SPHK2, and PARP1 were relatively increased, the protein expression levels of E-cadherin and ZO-1 were relatively reduced (P < 0.05), and the protein expression levels of N-cadherin, β-catenin, vimentin, and α-SMA were relatively increased (P < 0.05). In the negative control and experiment groups, the protein expression levels of AR, p-AR, CYP17A1, SPHK2, and PARP1 were relatively decreased (P < 0.05), the protein expression levels of E-cadherin and ZO-1 were relatively increased (P < 0.05), and the protein expression levels of N-cadherin, β-catenin, vimentin and α-SMA were relatively decreased (P < 0.05). Conclusion: Lathyrol and cisplatin inhibit the proliferation of RCC xenografts, reduce the protein expression levels of AR, CYP17A1, SPHK2, PARP1, E-cadherin, and ZO-1 in tumor tissues (P < 0.05), and promote the protein expression levels of N-cadherin, β-catenin, vimentin and α-SMA (P < 0.05). Therefore, Lathyrol reduces RCC invasion and EMT by affecting the expression of AR and SPHK2 in RCC mice.
- 4 July 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-17
Open AccessLathyrol reduces the RCC invasion and incidence of EMT via affecting the expression of AR and SPHK2 in RCC mice
Objective: To investigate the effects of Lathyrol on the expression of androgen receptor (AR) and sphingosine kinase 2 (SPHK2) in renal cell carcinoma (RCC) mice and to further explore the mechanism by which Lathyrol inhibits the invasion and incidence of epithelial-mesenchymal transition (EMT). Methods: An RCC xenograft mouse model was constructed, and the mice were randomly divided into a model group, an experiment group and a negative control group. The experiment group was intragastrically gavaged with Lathyrol solution (20 mg/kg), the model group was intragastrically gavaged with 0.9% NaCl (same volume as that used in the experiment group), and the negative control group was injected intraperitoneally with 2 mg/kg cisplatin aqueous solution. Changes in the body weight and tumor volume of the mice were recorded. Western blot (WB) was used to assess the protein expression levels of AR, p-AR, CYP17A1, PARP1, E-cadherin, N-cadherin, vimentin, α-SMA, β-catenin, and ZO-1. Protein expression levels of SPHK2, metal matrix protease 2 (MMP2), MMP9 and urokinase-type plasminogen activator (uPA) in tumor tissues were assessed by immunohistochemistry (IHC). AR expression in tumor tissues was assessed after immunofluorescence (IF) staining. Results: After 14 days of drug administration, compared with that in the model group, the tumor volumes in the negative control and experiment groups were lower; the difference in tumor volume among the model, control and experiment groups was statistically significant (P < 0.05). The differences in body weight among the three groups were not statistically significant (P > 0.05). In the model group, the protein expression levels of AR, p-AR, CYP17A1, SPHK2, and PARP1 were relatively increased, the protein expression levels of E-cadherin and ZO-1 were relatively reduced (P < 0.05), and the protein expression levels of N-cadherin, β-catenin, vimentin, and α-SMA were relatively increased (P < 0.05). In the negative control and experiment groups, the protein expression levels of AR, p-AR, CYP17A1, SPHK2, and PARP1 were relatively decreased (P < 0.05), the protein expression levels of E-cadherin and ZO-1 were relatively increased (P < 0.05), and the protein expression levels of N-cadherin, β-catenin, vimentin and α-SMA were relatively decreased (P < 0.05). Conclusion: Lathyrol and cisplatin inhibit the proliferation of RCC xenografts, reduce the protein expression levels of AR, CYP17A1, SPHK2, PARP1, E-cadherin, and ZO-1 in tumor tissues (P < 0.05), and promote the protein expression levels of N-cadherin, β-catenin, vimentin and α-SMA (P < 0.05). Therefore, Lathyrol reduces RCC invasion and EMT by affecting the expression of AR and SPHK2 in RCC mice.
- Open Access
- 8 February 2024
- Published by Springer Nature in Research Square
Lathyrol Reduces the RCC Invasion and Incidence of EMT via Affecting the Expression of AR and SPHK2 in RCC mice
Objective: To investigate the effects of Lathyrol on the expression of androgen receptor (AR) and sphingosine kinase 2 (SPHK2) in renal cell carcinoma (RCC) mice and to further explore the mechanism by which Lathyrol inhibits the invasion and incidence of epithelial-mesenchymal transition (EMT). Methods: An RCC xenograft mouse model was constructed, and the mice were randomly divided into a model group, an experiment group and a negative control group. The experiment group was intragastrically gavaged with Lathyrol solution (20 mg/kg), the model group was intragastrically gavaged with 0.9% NaCl (same volume as that used in the experiment group), and the negative control group was injected intraperitoneally with 2 mg/kg cisplatin aqueous solution. Changes in the body weight and tumor volume of the mice were recorded. Western blot (WB) was used to assess the protein expression levels of AR, p-AR, CYP17A1, PARP1, E-cadherin, N-cadherin, vimentin, α-SMA, β-catenin, and ZO-1. Protein expression levels of SPHK2, metal matrix protease 2 (MMP2), MMP9 and urokinase-type plasminogen activator (uPA) in tumor tissues were assessed by immunohistochemistry (IHC). AR expression in tumor tissues was assessed after immunofluorescence (IF) staining. Results: After 14 days of drug administration, compared with that in the model group, the tumor volumes in the negative control and experiment groups were lower; the difference in tumor volume among the model, control and experiment groups was statistically significant (P0.05). In the model group, the protein expression levels of AR, p-AR, CYP17A1, SPHK2, and PARP1 were relatively increased, the protein expression levels of E-cadherin and ZO-1 were relatively reduced (P PPPConclusion: Lathyrol and cisplatin inhibit the proliferation of RCC xenografts, reduce the protein expression levels of AR, CYP17A1, SPHK2, PARP1, E-cadherin, and ZO-1 in tumor tissues (PP<0.05). Therefore, Lathyrol reduces RCC invasion and EMT by affecting the expression of AR and SPHK2 in RCC mice.
- 8 February 2024
- Published by Springer Nature in Research Square
Open AccessLathyrol Reduces the RCC Invasion and Incidence of EMT via Affecting the Expression of AR and SPHK2 in RCC mice
Objective: To investigate the effects of Lathyrol on the expression of androgen receptor (AR) and sphingosine kinase 2 (SPHK2) in renal cell carcinoma (RCC) mice and to further explore the mechanism by which Lathyrol inhibits the invasion and incidence of epithelial-mesenchymal transition (EMT). Methods: An RCC xenograft mouse model was constructed, and the mice were randomly divided into a model group, an experiment group and a negative control group. The experiment group was intragastrically gavaged with Lathyrol solution (20 mg/kg), the model group was intragastrically gavaged with 0.9% NaCl (same volume as that used in the experiment group), and the negative control group was injected intraperitoneally with 2 mg/kg cisplatin aqueous solution. Changes in the body weight and tumor volume of the mice were recorded. Western blot (WB) was used to assess the protein expression levels of AR, p-AR, CYP17A1, PARP1, E-cadherin, N-cadherin, vimentin, α-SMA, β-catenin, and ZO-1. Protein expression levels of SPHK2, metal matrix protease 2 (MMP2), MMP9 and urokinase-type plasminogen activator (uPA) in tumor tissues were assessed by immunohistochemistry (IHC). AR expression in tumor tissues was assessed after immunofluorescence (IF) staining. Results: After 14 days of drug administration, compared with that in the model group, the tumor volumes in the negative control and experiment groups were lower; the difference in tumor volume among the model, control and experiment groups was statistically significant (P0.05). In the model group, the protein expression levels of AR, p-AR, CYP17A1, SPHK2, and PARP1 were relatively increased, the protein expression levels of E-cadherin and ZO-1 were relatively reduced (P PPPConclusion: Lathyrol and cisplatin inhibit the proliferation of RCC xenografts, reduce the protein expression levels of AR, CYP17A1, SPHK2, PARP1, E-cadherin, and ZO-1 in tumor tissues (PP<0.05). Therefore, Lathyrol reduces RCC invasion and EMT by affecting the expression of AR and SPHK2 in RCC mice.
- Open Access
- 12 April 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-16
Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes
Background. Bladder cancer (BLCA) is one of the most common cancers and ranks ninth among all cancers. Extracellular matrix (ECM) genes activate a number of pathways that facilitate tumor development. This study is aimed at providing models to predict BLCA survival and recurrence by ECM genes. Methods. Expression data from BLCA samples in GSE32894, GSE13507, GSE31684, GSE32548, and TCGA-BLCA cohorts were downloaded and analyzed. The ECM-related genes were obtained by differentially expressed gene analysis, stage-associated gene analysis, and random forest variable selection. The ECM was constructed in GSE32894 by the hub ECM-related genes and validated in GSE13507, GSE31684, GSE32548, and TCGA-BLCA cohorts. The correlations of the ECM score with cells (T cells, fibroblasts, etc.) and the response to immunotherapeutic drugs were investigated. Four machine learning models were selected and used to construct models to predict the recurrence of BLCA. A total of 15 paired BLCA and normal tissue specimens, human immortalized uroepithelial cell lines, and bladder cancer cell lines were selected for the validation of the difference in expression of FSTL1 between normal tissues and BLCA. Results. Six ECM genes (CTHRC1, MMP11, COL10A1, FSTL1, SULF1, and COL5A3) were recognized to be the hub ECM-related genes. The ECM score of each BLCA patient was calculated using these six selected ECM-related genes. BLCA patients with a high ECM score group had significantly lower overall survival rates than patients in the low ECM score group. We found that the ECM score was positively associated with immune cells and fibroblasts and negatively correlated with tumor purity. When treated with immunotherapy, BLCA patients with a high ECM score presented a high response rate and better prognosis. We also found that the combination of FSTL1, stage, age, and gender achieved an AUC value of 0.76 in predicting bladder cancer recurrence. Based on the RT-qPCR results of FSTL1 gene expression, there was an overall decrease in the mRNA expression of FSTL1 in cancer tissues compared to their adjacent normal tissues. Subsequent in vitro validation demonstrated that the FSTL1 expression was downregulated at the gene and protein level compared to that in SVH cells. Conclusion. Taken together, our results indicate that ECM-related genes correlate with immune cells, overall survival, and recurrence of BLCA. This study provides a machine learning model for predicting the survival and recurrence of BLCA patients.
- 12 April 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-16
Open AccessPrediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes
Background. Bladder cancer (BLCA) is one of the most common cancers and ranks ninth among all cancers. Extracellular matrix (ECM) genes activate a number of pathways that facilitate tumor development. This study is aimed at providing models to predict BLCA survival and recurrence by ECM genes. Methods. Expression data from BLCA samples in GSE32894, GSE13507, GSE31684, GSE32548, and TCGA-BLCA cohorts were downloaded and analyzed. The ECM-related genes were obtained by differentially expressed gene analysis, stage-associated gene analysis, and random forest variable selection. The ECM was constructed in GSE32894 by the hub ECM-related genes and validated in GSE13507, GSE31684, GSE32548, and TCGA-BLCA cohorts. The correlations of the ECM score with cells (T cells, fibroblasts, etc.) and the response to immunotherapeutic drugs were investigated. Four machine learning models were selected and used to construct models to predict the recurrence of BLCA. A total of 15 paired BLCA and normal tissue specimens, human immortalized uroepithelial cell lines, and bladder cancer cell lines were selected for the validation of the difference in expression of FSTL1 between normal tissues and BLCA. Results. Six ECM genes (CTHRC1, MMP11, COL10A1, FSTL1, SULF1, and COL5A3) were recognized to be the hub ECM-related genes. The ECM score of each BLCA patient was calculated using these six selected ECM-related genes. BLCA patients with a high ECM score group had significantly lower overall survival rates than patients in the low ECM score group. We found that the ECM score was positively associated with immune cells and fibroblasts and negatively correlated with tumor purity. When treated with immunotherapy, BLCA patients with a high ECM score presented a high response rate and better prognosis. We also found that the combination of FSTL1, stage, age, and gender achieved an AUC value of 0.76 in predicting bladder cancer recurrence. Based on the RT-qPCR results of FSTL1 gene expression, there was an overall decrease in the mRNA expression of FSTL1 in cancer tissues compared to their adjacent normal tissues. Subsequent in vitro validation demonstrated that the FSTL1 expression was downregulated at the gene and protein level compared to that in SVH cells. Conclusion. Taken together, our results indicate that ECM-related genes correlate with immune cells, overall survival, and recurrence of BLCA. This study provides a machine learning model for predicting the survival and recurrence of BLCA patients.